siklos
theravia - hydroksykarbamid - anemi, sickle cell - antineoplastiske midler - siklos er indikert for forebygging av tilbakevendende smertefulle vaso-occlusive kriser, inkludert akutt brystet syndrom i paediatric og voksne pasienter som lider av symptomatisk sickle-cell syndrom.
hydroxyurea medac 500 mg
medac gesellschaft für klinische spezialpräparate mbh - hydroksykarbamid - kapsel, hard - 500 mg
karbamid evolan 50 mg/ g
evolan pharma ab - urea - krem - 50 mg/ g
xromi
nova laboratories ireland limited - hydroksykarbamid - anemi, sickle cell - antineoplastiske midler - forebygging av vaso-occlusive komplikasjoner av sigdcelleanemi hos pasienter over 2 år.
hydrea 500 mg
orifarm as - hydroksykarbamid - kapsel, hard - 500 mg
hydrea 500 mg
orifarm as - hydroksykarbamid - kapsel, hard - 500 mg
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
adakveo
novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
canomini 20 mg/ g / 200 mg/ g
aco hud nordic ab - urea / glyserol - krem - 20 mg/ g / 200 mg/ g